Conditions:   Non Small Cell Lung Cancer;   KRAS Activating Mutation;   Advanced Cancer;   Metastatic Cancer;   Malignant Neoplasm of Lung;   Malignant Neoplastic Disease
Intervention:   Drug: VS-6766 and adagrasib
Sponsors:   Verastem, Inc.;   Mirati Therapeutics Inc.
Not yet recruiting